Stock AnalizAstrazeneca (AZN) earnings for the quarter ended September 2026: EPS misses estimates
Astrazeneca reported results for the quarter ended September 2026 on October 30, 2026. Adjusted earnings per share came in at $1.00 against the analysts’ average forecast of $1.15, a miss of 12.7%.
Revenue for the quarter was $16.21 billion, up 6.7% from $15.19 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 7.0% on the first trading day after the report.
The last four quarters
Astrazeneca has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.00 | $1.15 | −12.7% | +7% | +7.0% |
| Jun 2026 | $1.31 | $1.25 | +4.8% | — | +1.9% |
| Mar 2026 | $1.29 | $1.27 | +1.4% | — | +0.4% |
| Sep 2025 | $1.19 | $1.14 | +4.4% | — | +0.5% |
What comes next
Analysts expect EPS of $1.74 for the next quarter on average and $10.12 for the fiscal year ending December 31, 2026.
The average analyst price target is $208.07, 13% above the current price of $184.45.
Valuation and score
Astrazeneca scores 2.8 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 26.1, and its intrinsic value under moderate assumptions is about 38% below the current market value. Full Astrazeneca analysis with 10 years of financials
Frequently asked questions
What was Astrazeneca’s EPS for the quarter ended September 2026?
$1.00 adjusted per share, against an analyst consensus of $1.15.
How much revenue did Astrazeneca report?
$16.21 billion, up 6.7% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.